Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Pariser

Showing results (101-110 of 115) with videos related to

Pageof 12
Sort By:
Advances in Therapy|February 11, 2025
Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability StudyMark G Lebwohl, John Y Koo, Janusz Jaworski, et al.
International Journal of Dermatology|January 13, 2010
Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studiesPeter Foley, Michael Freeman, Alan Menter, et al.
Dermatology and Therapy|October 24, 2025
Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III TrialsKim A Papp, James Q Del Rosso, Mark G Lebwohl, et al.
Journal of the American Academy of Dermatology|November 6, 2007
From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasisMark Lebwohl, Jerry Bagel, Joel M Gelfand, et al.
The British Journal of Dermatology|June 6, 2023
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb studyLeon H Kircik, Javier Alonso-Llamazares, Neal Bhatia, et al.
American Journal of Clinical Dermatology|November 1, 2025
Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 WeeksAndrew F Alexis, Michael Bukhalo, Fran E Cook-Bolden, et al.
JAMA Dermatology|May 3, 2023
Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical TrialMatthew J Zirwas, Zoe D Draelos, Janet DuBois, et al.
BMC Cancer|February 7, 2018
Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patientsJonathan S Zager, Brian R Gastman, Sancy Leachman, et al.
Journal of Drugs in Dermatology : JDD|February 21, 2006
The use of photodynamic therapy in dermatology: results of a consensus conferenceMark S Nestor, Michael H Gold, Arielle N B Kauvar, et al.
JAMA|September 20, 2022
Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical TrialsMark G Lebwohl, Leon H Kircik, Angela Y Moore, et al.
Pageof 12

Showing results (101-110 of 115) with videos related to

Sort By:
Pageof 12
Advances in Therapy|February 11, 2025
Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability StudyMark G Lebwohl, John Y Koo, Janusz Jaworski, et al.
International Journal of Dermatology|January 13, 2010
Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studiesPeter Foley, Michael Freeman, Alan Menter, et al.
Dermatology and Therapy|October 24, 2025
Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III TrialsKim A Papp, James Q Del Rosso, Mark G Lebwohl, et al.
Journal of the American Academy of Dermatology|November 6, 2007
From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasisMark Lebwohl, Jerry Bagel, Joel M Gelfand, et al.
The British Journal of Dermatology|June 6, 2023
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb studyLeon H Kircik, Javier Alonso-Llamazares, Neal Bhatia, et al.
American Journal of Clinical Dermatology|November 1, 2025
Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 WeeksAndrew F Alexis, Michael Bukhalo, Fran E Cook-Bolden, et al.
JAMA Dermatology|May 3, 2023
Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical TrialMatthew J Zirwas, Zoe D Draelos, Janet DuBois, et al.
BMC Cancer|February 7, 2018
Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patientsJonathan S Zager, Brian R Gastman, Sancy Leachman, et al.
Journal of Drugs in Dermatology : JDD|February 21, 2006
The use of photodynamic therapy in dermatology: results of a consensus conferenceMark S Nestor, Michael H Gold, Arielle N B Kauvar, et al.
JAMA|September 20, 2022
Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical TrialsMark G Lebwohl, Leon H Kircik, Angela Y Moore, et al.
Pageof 12